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                                          ABSTRACT 
 
 
Background 
Carcinoma of the breast has clinical heterogeneity with high morbidity and 
mortality. Determination of prognostic factors is important in improving the 
overall survival breast cancer patients. Her2/neu is one of the powerful predictors 
of poor prognosis. Thus a study of Her2/neu expression estimated by 
immunohistochemistry in breast cancer is the need of the hour. This study 
investigates correlations between the presence of Her2/neu and various 
clinicopathological prognostic parameters in primary breast carcinomas. 
 
Objectives 
         1. Study of  the HER2/neu status in breast   carcinomas   in the  study  sample. 
         2. To find   the   association of    HER2/neu    status    with  clinicopathological 
              prognostic parameters in breast carcinomas in the study sample. 
         3. To find   the  association  of   HER2/neu  status   with  lymph  node  status. 
 
 Methodology 
           Patients diagnosed as carcinoma breast, admitted in Department of General 
surgery, Govt. Royapettah Hospital and post operative modified radical mastectomy 
specimens were examined for gross and microscopic features. 
Immunohistochemistry was used to study the Her2/ neu expression. Her2/neu status 
was correlated with various clinicopathological prognostic parameters. 
  
Results 
 
There was a significant statistical association between Her2/neu expression 
with lymph node status(p=0.012) and presenting symptoms such as pain  and nipple 
discharge. Expression of Her2/ neu expression was increased in tumour size of more 
than 2 cms (64%) and higher tumour grade (90%). The major histological subtype 
was Infiltrating duct carcinoma, NOS type. Meanwhile there was no significant 
association of Her2/neu expression with menopausal status, NPI groups and other 
histological parameters. 
 
Conclusion 
 
Our study data indicates that Her2/neu may be a more powerful predictor for 
poor prognosis as its expression is associated with important prognostic 
parameters like increased tumour size,  high tumour grade, high NPI score and 
lymph node involvement. 
Key words  
                      Immunohistochemistry; Her2/ neu; breast carcinoma; 
clinicopathologicalprognostic parameters; Nottingham modification of Scarff Bloom 
Richardson grading (NSBR grading); Nottingham Prognostic Index. 
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INTRODUCTION 
 
 
Breast carcinoma is the most common malignant tumour. It is the leading 
cause of death due to carcinoma in women. It has an incidence of more than one 
million cases  reported from all over the world1. It is of serious concern owing to the 
rising incidence of the disease both in the developed and developing countries2. 
In India, breast cancer was the second to lung carcinoma in its incidence in 
women prior to 1990 (Takiar and Srivastav, 2008) but now it occupies the top rank 
among cancers in women in India owing to the gradual change in lifestyle of Indian 
women3. In India most of the patients present with palpable cancer and even with 
lymph  node metastasis at the time of their first visit. 4. 
Breast cancer is not  a single disease but it is a disease with multiple distinct 
biological subtypes and varied natural history. It has a wide spectrum of clinical, 
pathological and molecular features which alter prognosis and management. Over 
the last few decades there have been outstanding advances in breast cancer 
management resulting in drastic decrease in mortality and decreased morbidity for 
women living with disease5. 
Stratification of patients after taking into consideration various prognostic 
parameters has assumed a great therapeutic importance1. Histopathological 
examination of the primary carcinoma and the axillary lymph nodes is a major 
prognostic indicator. Many prognostic and predictive factors have been identified by 
the College of American Pathologists to guide the clinical management of women 
with breast cancer. The prognostic factors includes invasive carcinoma or in-situ 
disease, distant metastases, lymph node metastases, tumour size, locally advanced 
2 
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disease, histologic grade, histologic subtype,  inflammatory carcinoma and  hormonal 
receptor status and increased expression of HER2/neu6. 
In the current management guidelines, estrogen receptor (ER), progesterone 
receptor (PR) status and overexpression of HER2/neu are the three most useful 
predictive factors for response to specific therapeutic agents4. 
HER2/neu, otherwise known as neu or c-erbB-2, is the product of  an 
oncogene. Its amplification and over expression varies from 11% to 32% of 
breast carcinomas7. Today Immunohistochemistry (IHC) is the centre stage in the 
demonstration   of   newer   monoclonal   antibodies8.   IHC   is   used   commonly 
for evaluating Her2/neu protein expression in breast cancer. Her2/neu expression is 
an independent prognostic factor in patients with both node- positive and node-
negative breast cancer. 
HER2/neu has greater prognostic value than most currently used prognostic 
factors including ER, PR status9. HER2/neu positive cancers exhibit resistance to 
tamoxifen but not to aromatase inhibitors or ovarian ablation10. 
The presence of HER2/neu is related to a high grade tumour and poor 
prognosis but favourable response to monoclonal antibody therapy and disease 
survival11. Therefore, there is a growing clinical demand for analysis of the  
Her2/neu status of current and archived breast cancer specimens12. 
 
 
 
 
                                                                               3 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
 
 
 
 
 
 
Aims & Objectives 
  
 
 
 
 
     AIMS AND OBJECTIVES 
 
         
 
 1. Study of  the HER2/neu status in breast carcinomas in the study sample. 
 2. To find the association of HER2/neu status with clinicopathological     prognostic  
parameters in breast carcinomas in the study sample. 
 3. To find the association of  HER2/neu status with lymph node status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                             5 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                    6 
 
 
 
Review of Literature 
  
 
REVIEW OF LITERATURE 
 
 
History 
The first reference to breast cancer dates back to “The Edwin Smith Surgical 
Papyrus” (3000-2500 BC), that mentions the diagnosis and treatment of eight cases 
of ailments of the breast. The author writes that there is no treatment for the 
breast tumours that are cool to touch and are bulging13. 
A detail account of breast cancer cases was described by Hippocrates. He 
described tumours in the breast became increasingly firm, with no pus. They 
eventually spread to other parts of the body, accompanied by shooting pain radiating 
from the breast to the neck and shoulder blades. The death was certain with the 
development of thirst and emaciation. He advised not to treat the hidden cancers13. 
The manuscript, „De Medicina‟, written by Celsus, defined four stages of 
breast cancer. The first stage was cacoethes (inflammation), followed by 
carcinoma without skin ulceration and later carcinoma with ulceration. The final 
stage was advanced exophytic and sometimes bleeding lesion, called the “thymium” 
which resembled the flowers of thyme. Celsus recommended excision for cacoethes 
and no treatment for other stages. In situations of uncertainty, the tumour was 
first treated with caustics and if symptoms improved, then it was cacoethes. If they 
worsened, then it was a carcinoma. Some masses for which treatment was successful 
might have been fibroadenomas, phyllodes tumours or even tuberculosis13. The 
nineteenth century witnessed remarkable advancements in human pathology and in 
the safety of surgery13  
      7 
  
The advent of microscope by Anton Van Leuwenhoek (1674-1723) triggered 
the world of microscopic anatomy and Germany became the pioneer of 
„compound achromatic microscope‟13. 
Johannes Muller (1801-1859) was the first to report that cancers also were 
composed of living cells13. 
The advancements in the surgical field brought modified mastectomies into 
existence. For the fear of spreading cancer with a biopsy, diagnosis  was almost 
always clinical, established histologically only after the operation13. 
The discovery of x-rays provided the basis for radiotherapy and 
mammography13. The next 100 years resulted in a retreat from radical surgery with 
the introduction of mammography and chemotherapy. Breast cancer was recognized 
as a major health problem in the western world, stimulating a concerted effort 
against it13. 
Evolution of a prognostic index in breast carcinoma 
Von H ansemann is credited for initiating many of the histological grading 
systems used today. He assessed the degree of nuclear anaplasia in tumours and 
noted that, the greater the degree of nuclear atypia, the greater is the likelihood of a 
metastasis occurring14. 
An association was found between the degree of differentiation and prognosis 
in patients with squamous carcinoma of the lip by Broders in 1920. Greenough 
subsequently developed a grading method for breast carcinoma that separated 
tumours into three histological grades based on histological and cytological features. 
      8 
  
The features taken into account were the amount of tubule formation, the secretory 
activity of cells, the overall size of cells and nuclei, variation in the size of both 
cells and nuclei; nuclear hyperchromatism, and mitotic activity14. 
Greenough‟s method was simplified by Patey and Scarff that considered only 
three factors namely the tubule formation, variation in nuclear size and shape 
and nuclear hyperchromatism14. 
In 1957, Bloom and Richardson introduced a numerical scoring system to the 
method described by Patey and Scarff11. It combined the details of cell 
morphology (nuclear pleomorphism) with a measurement of differentiation (tubule 
formation) and an assessment of proliferation (mitotic frequency) 15. 
A large study of 2219 cases were systematically studied by Emad Rakha et al 
in 1957 and concluded that histological grade, as assessed by the Nottingham 
modification of Bloom Richardson histological grading system, provides a strong 
predictor of outcome in patients with invasive breast cancer and should be 
incorporated in breast cancer staging systems16. 
A great many prognostic factors in breast cancer have been described, but few 
when placed in multivariate analysis retain independent significance. Prognosis is 
multifactorially determined and the best discrimination is achieved by integrating 
independently significant factors. A widely used method of integration is the 
Nottingham Prognostic Index (NPI), first described in 1982. It is the only Index 
to have both intra- and inter-centre prospective validation17. 
                                                  9 
  
The earlier studies divided patients into three NPI groups but Blamey et al 
(2007) recognized six groups: an Excellent Prognostic Group (EPG) with an 
observed NPI  range  of  2.08–2.4,  Good  Prognostic  Group  (GPG)  2.42  to  63.4;    
Moderate Prognostic Group I  (MPG I) 3.42 to  64.4, Moderate  Prognostic Group  II 
(MPG   II) 4.42 to 65.4, Poor Prognostic Group (PPG) 5.42 to 66.4 and Very 
poor Prognostic Group (VPG) > 6.517. 
The WHO has adopted the NPI consisting of the tumour size, tumour grade 
and lymph node status5. 
Prognostic parameters in breast carcinoma 
Prognostic factors, although not specific predictors of response to a therapy, is 
helpful for selection of appropriate treatment to patients with malignancies. 
Patients with an extremely good prognosis after tumour excision may not require 
noxious adjuvant therapies which themselves carry significant morbidity18. 
Conversely, patients with a poor prognosis may benefit from an aggressive 
adjuvant approach. Thus, identification of the prognostic features of an invasive 
breast carcinoma is particularly important as the disease has a markedly variable 
course19. A group of women with curable carcinomas who do not receive significant 
benefit from adjuvant therapy can be identified, while others will succumb relatively 
rapidly to the disease20. Because of this widely differing clinical outcome and 
because of the commonness of breast cancer, prognostic factors and, more recently, 
predictive factors in this malignant disease are probably among the most widely 
studied18,21.                                                          10 
  
Many recent studies of possible prognostic factors in primary breast cancer 
have taken into account novel variables, either morphologically, 
immunohistochemically or biochemically, which at least experimentally are 
associated with invasion, metastasis, differentiation or growth rate of the tumour18, 21. 
The prognosis of breast carcinoma is related to a   number     of   clinical    and 
pathologic parameters. These are as follows: 
1. Age of patient: Women younger than 50 years of age at the time of diagnosis 
have the best prognosis and is low in case of older women. Relative survival 
declines after the age of 50 years1, 22. 
2. BRCA1 status: A worse overall survival has been noted in breast carcinomas 
with BRCA1 mutation carriers in the absence of adjuvant therapy1, 23. 
3. Pregnancy and oral contraceptives: Carcinoma of the breast manifesting during 
pregnancy or lactation is generally aggressive tumour with low expression of 
hormone receptors and high expression of Her2/neu and is associated with poor 
prognosis. However, no convincing evidence has been found that prior use of oral 
contraceptive agents has an effect on the evolution or survival of breast 
carcinoma1. 
4. Early diagnosis: The relative survival rates for asymptomatic breast carcinomas 
are higher than those for clinically detectable carcinomas1. 
5. Presence or absence of invasiveness: Majority of women with adequately treated 
DCIS are cured. In contrast, at least half of the invasive carcinomas have 
metastasized locally or distantly at the time of diagnosis4. 
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6. Size: There is a good correlation between the diameter of the primary tumour 
and the incidence of nodal metastasis and the survival rate24. The risk of axillary 
lymph node metastases increases with the size of primary tumour1. 
7. Histological type: The  favourable    prognosis of certain histologic types of 
invasive carcinoma of the breast is now well recognized. Thus, tubular carcinoma 25, 
26, 27, mucinous carcinoma28, 29, invasive cribriform carcinoma30, medullary  
carcinoma31,  32,  infiltrating  lobular  carcinoma33   and tubulo-lobular 
carcinoma34 have been reported to have a more favourable prognosis than invasive 
duct carcinomas of no special type18. 
8. Histological grade: Histological grade is an important determinant of prognosis 
that allows risk stratification within a given tumour stage. Morphological assessment 
of the degree of differentiation provides useful prognostic information in breast 
cancer. It has been recommended that all invasive breast carcinomas should be 
graded and the grading system used must be specified in the report. Grading is not 
restricted to tumours of no special histological type but special types are also 
included18. The most commonly used grading  system, the Nottingham 
modification of Scarff-Bloom-Richardson grading (NSBR grading), combines nuclear 
grade, tubule formation, and mitotic rate 24. 
9. Type of margins: Tumours with infiltrating margins have a poorer prognosis 
than tumours with pushing margins1. 
10. Tumour necrosis: There is an increased incidence of lymph node metastases and 
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decreased survival rates associated with tumour necrosis, particularly if it is 
extensive. This feature is usually associated with tumours of high histologic 
grade1. 
11. Stromal reaction: Tumours with a presence of inflammatory reaction at the 
periphery have a higher degree of nodal metastases and presumably poorer 
prognosis1. 
12. Skin invasion: A decreased survival rate is seen in breast carcinomas with 
invasion of the overlying skin1. 
13. Nipple invasion: Invasion of nipple by carcinoma is associated with a higher 
incidence of axillary metastases1. 
14. Lymphatic tumour emboli: There is an increased risk of tumour recurrence if 
there is presence of tumour emboli in the lymphatic vessels1. 
15. Blood vessel emboli: There is a high correlation between the presence of tumour 
emboli in the blood vessels and tumour size, histological grade, tumour type, 
lymph node status, development of distant metastases and poor prognosis1. 
16. Axillary lymph node metastases: Lymph node staging provides very powerful 
prognostic information in breast cancer. It is now generally accepted that the 
staging should be based on histologic examination of excised nodes rather than 
clinical examination. Numerous studies have shown that patients who have 
histologically involved regional lymph nodes have a much  poorer prognosis than 
those without nodal involvement. The greater the number and the level of 
lymph nodes involved, the poorer the prognosis1. 
17. Internal mammary lymph node metastases: There is decreased survival rate in 
13 
  
patients with involvement of internal mammary lymph nodes compared to those 
without the involvement of these nodes1. 
18. Distant metastases: A cure is unlikely once the distant metastases are present 
and is associated with poor prognosis1. 
Review of Histological grading 
The morphologic appearance of tumours can be correlated with their degree of 
malignancy18. Nearly 70 years ago, Scarff and his colleagues revised 
Greenhoughs method. The NSBR grading was adopted by WHO35. Morphological 
assessment of the degree of differentiation provides useful prognostic information in 
breast cancer, so now histological grading has been accepted as a routine procedure 
due to problems perceived with reproducibility and consistency15. It has been 
recommended that all invasive breast carcinomas should be graded and the 
grading system used must be specified in the report. Most of the special types of 
breast carcinoma are associated with a favourable prognosis, but this is generally 
true only for tumours with low-grade cytology. However, medullary carcinoma has a 
better prognosis than what the grading would suggest36. 
Histological grade is an important prognostic marker that allows risk 
stratification within a given tumour stage36. There are several histological 
grading systems in use; some consider ductoglandular differentiation or  tumour 
secretory state. Some score only nuclear and nucleolar characteristics and others use 
both duct formation and nuclear abnormalities37. The most commonly used grading 
system, the NSBR grading, combines nuclear grade, tubule formation, and mitotic 
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rate (Table-1). Histological grade provides prognostic information along with the 
stage of disease. Poorly differentiated tumours are known to pursue a more 
aggressive course than their well differentiated counterparts33, 38, 39, 40. 
The WHO has adopted the Nottingham Prognostic Index consisting of the 
tumour size, tumour grade and lymph node status5. 
Review of immunohistochemistry 
Immunohistochemistry (IHC) or immunocytochemistry is a method for 
localizing specific antigens in tissues or cells based on antigen antibody  recognition. 
It seeks to exploit the specificity provided by the binding of an antibody with its 
antigen at a light microscopic level. IHC has a long history, extending more than half 
a century from 1940, when Coons developed an immunofluorescence technique 
to detect corresponding antigens in frozen tissue sections. However, only since the 
early 1990s has the method found general application in surgical pathology. A 
series of technical developments led eventually to the wide range of IHC 
applications in use today. The enzymatic label (horseradish peroxidase), developed 
by Avrameas and by Nakane  and  colleagues,  allowed  visualization  of  the  
labeled  antibody  by      light  microscopy in the presence of a suitable colourogenic 
substrate system41. 
In Oxford, Taylor and Burns in 1974 developed the first successful 
demonstration of antigens in routinely processed formalin fixed paraffin- 
embedded (FFPE) tissues. Critical issue in the development of immunoperoxidase 
techniques was related to the need to achieve greater sensitivity. Greater sensitivity 
would facilitate staining of FFPE tissues from a simple one- step direct conjugate 
15 
  
method to multiple- step detection techniques such as the peroxidase antiperoxidase 
(PAP), avidin-biotin conjugate (ABC), and biotin streptavidin (B-SA) methods 
and would eventually lead to amplification methods (such as tyramide) and highly 
sensitive polymer- based labeling systems. As the IHC method has evolved, its use  
in diagnostic pathology has expanded such that the use of one or more IHC stains 
is routine in surgical pathology, especially with respect to tumour diagnosis and 
classification. IHC has also been adapted to the identification and demonstration 
of both prognostic and predictive markers41. 
Enzyme digestion was introduced by Huang as a pre-treatment to IHC staining 
to unmask some antigens that had been altered by formalin fixation. The 
antigen- retrieval (AR) technique, based on a series of biochemical studies by 
Fraenkel- Conrat and coworkers was developed by Shi et al in 1991. In contrast to 
enzyme digestion, the AR technique is a simple method that involves heating 
routinely processed paraffin sections at high temperature before IHC staining 
procedures. The intensity of IHC staining was increased dramatically after AR pre-
treatment.  Subsequently various modifications of the AR technique have been 
described. Worldwide application of AR- IHC in pathology has validated the 
feasibility of AR-IHC and expanded its use in molecular morphology, while 
raising some basic questions and practical issues that are subject to ongoing 
evolution of the method42. 
The “College of American Pathologists Consensus Statement” has defined three 
categories of prognostic markers. The Category I includes factors of proven 
histological importance and are useful in clinical management namely the TNM 
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staging, the histological grade, the histological subtype, the mitotic count and the 
hormone receptor status. These factors hence become mandatory inclusions for a 
breast pathology report. The category II factors are extensively studied biologically 
and clinically but their importance remains to be validated with more robust studies. 
The factors are Human epidermal growth factor receptor2/ neuroblastoma 
(HER2/neu), lymphovascular invasion, p53, proliferative markers (MIB-1). The 
category III factors are not yet sufficiently  studied  to  prove  their  prognostic  value.  
These  include  DNA ploidy, microvessel density, EGFR, Bcl2, pS2 and Cathepsin 
D5,6. 
Biologic markers in   normal breast 
 Estrogen Receptor43: 
  It can be demonstrated in the nuclei of both ductal and lobular  epithelial  cells, 
with a higher proportion in lobules than in ducts. 
  However, even in the lobules, only a small proportion of the cells show ER 
immunoreactivity, thus leading to heterogeneity of ER expression. 
  In breast tissue from premenopausal women, there is generally an inverse 
relationship between expression of ER and markers of cell proliferation. 
  The  ER  positive  cells  do  not  show  expression  of  the  proliferation related 
antigen Ki-67, and the Ki-67-positive cells are typically ER- negative. 
  The proportion of ER-positive cells gradually increases with age but    remains 
relatively stable after the menopause. 
  The incidence of lobules showing contiguous patches of ER1 positive cells 
also increases with age and with involutional changes. 
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  In  premenopausal  women,  ER1  expression  varies  with  the  phase  of    the 
menstrual cycle, being higher in the follicular than in the luteal phase. 
  Myoepithelial cells do not show ER immunoreactivity. 
  Recent  studies  have  indicated  that  a  second  form  of  ER,  ER2,  is      also 
expressed in normal breast tissue. 
  Expression of ER2 has been observed not only in epithelial cells of ducts   and 
lobules, but also in myoepithelial cells, endothelial cells and stromal cells. 
  The expression of this form of ER2 does not seem to vary with the phase of the 
menstrual cycle. 
  It  has  been  speculated  that  the  relative  levels  of  ER1  and  ER2  may   be 
important in determining the risk of breast cancer development. 
  Higher  levels  of  ER2  relative  to  ER1   are  protective  against     neoplastic 
progression in the breast. 
  However, additional studies are needed to more clearly elucidate the role of 
ER2 in normal breast physiology and in breast cancer pathogenesis. 
Progesterone receptor (PR) 
 Has not been as extensively studied in normal breast tissue as has ER. 
 PR is expressed in the nuclei of ductal and lobular epithelium. 
 PR expression does not seem to vary with the menstrual cycle phase. 
Other biomarkers 
  Expression  of   a wide   variety of    biomarkers   has  been  studied  in benign  breast 
tissue. 
  Rarely, normal breast epithelium may show Her2/neu protein  overexpression, 
18 
  
p53 protein accumulation, or p53 mutations, but the clinical significance of these 
findings is uncertain. 
  The anti-apoptotic protein bcl-2 is consistently expressed by normal breast 
epithelial cells. 
  The S-100 protein  is  strongly expressed by normal  myoepithelial cells    and 
variably expressed by mammary epithelial cells. 
  Epithelial cells also  show  variable expression for casein, lactalbumin,    gross 
cystic disease fluid protein-15, and c-kit (CD117), among other proteins. 
  The cytokeratins 7, 8, 18, and 19 are typically expressed  by epithelial    cells, 
whereas myoepithelial cells express cytokeratins 5, 6, 14, and 17. 
Molecular prognostic markers in breast carcinoma 
Immunohistochemical analysis of prognostic and predictive factors like ER, 
PR, Ki-67, Her2/neu and p53 are being increasingly employed by the pathologists. 
Hormone receptors 
The normal breast epithelium contains receptors for estrogen  and 
progesterone. The interaction between these receptors and hormones stimulates the 
proliferation and differentiation of cells. About 60 – 70 % of breast carcinomas 
also express these receptors. The patients with estrogen receptor positive tumours 
have a longer survival rates than others44. 
HER- 2/neu 
HER- 2/neu also known as c-erb B- 2, is another proto-oncogene product 
associated with reduced survival when it is amplified and overexpressed in breast 
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cancer1. HER2/neu overexpression is associated with poor  survival, but its main 
importance is as a predictor of response to agents that target this transmembrane protein4. 
p53 
The p53 is a tumour  suppressor gene   normally    involved in  suppression  of   
the cell cycle. The p53 mutation and  overexpression  is seen in about 50% of  
breast cancers and are strongly associated with an increased tumour proliferation 
rate and poor clinical outcome44. 
Proliferation markers 
Proliferation can be measured by mitotic counts (e.g., as part of histologic 
grading), by immunohistochemical detection of cellular proteins produced during the 
cell cycle (e.g., cyclins, Ki-67), by flow cytometry (as the S-phase fraction), or 
by thymidine labeling index. Carcinomas with high proliferation rates have a 
poor prognosis but may respond better to chemotherapy4. 
DNA content 
The amount of DNA per tumour cell can be determined by flow-cytometric 
analysis or by image analysis of tissue sections. Tumors with a DNA index of 1 have 
the same total amount of DNA as normal diploid cells, although marked 
karyotypic changes may be present. Aneuploid tumours are those with abnormal 
DNA indices and have a slightly worse prognosis4. 
Telomerase activity 
The level of this enzyme is associated with the proliferative index of breast 
carcinoma, but its measurement is not an independent predictor of survival1. 
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Invasion related factors 
Several enzymes, when expressed by tumour cells or by the adjoining stroma, 
promote local invasion or distant metastasis leading to decreased survival. These 
include recently identified factors such as laminin receptor, cathepsin D,  stromolysin 
3 and urokinase- plasminogen activator44. 
Eighty percent of carcinomas that are both ER and PR positive respond to 
hormonal manipulation, whereas only about 40% of those with either ER or PR alone 
respond. ER-positive cancers are less likely to respond to chemotherapy. Conversely, 
cancers that fail to express either ER or PR have a less than 10% likelihood of 
responding to hormonal therapy but are more likely to respond to chemotherapy4. 
Osborne et al in 1996 reviewed the literature and concluded that tumours with 
higher levels of estrogen receptor have a greater response rate than those with 
lower amounts. Response to hormonal therapy requires functioning receptors, so a 
marker that reﬂects the functional integrity of the pathway, rather than simply the 
existence of receptor protein, could help separate receptor-positive patients who will 
respond from those who will not45. 
Allen Gown in 2008 reviewed the literature and concluded that the  presence 
of estrogen receptors (ERs), as detected by IHC, is a weak prognostic marker of 
clinical outcome in breast cancer, although a strong predictive marker for 
response, for example, to tamoxifen-based therapy46. 
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Review of HER2/neu 
HER2/neu is a 185 kDa glycoprotein with tyrosine kinase activity. It is also 
known as NEU, c-erbB- 2 or human epidermal growth factor receptor 211. It is a 
member of the human epidermal growth factor receptor gene family. Cells 
transfected with Her2/neu acquire a more malignant phenotype, with stimulation of 
cell proliferation, invasion, and metastasis47. 
ErbB-2 is a transmembrane growth factor receptor belonging to the type I 
receptor tyrosine kinase family of proteins. It is related to epidermal growth 
factor receptor (EGFR) and has high homology with other members of the EGFR 
family, which include ErbB-1, ErbB-3 and ErbB-4. The gene is located  on 
chromosome 17q21 and encodes a 185 kDa protein. It has 1255 amino acids and is a 
highly phosphorylated protein. Normally, ErbB-2 is expressed in a wide variety of 
tissues and is involved in normal growth, cell adhesion and development. ErbB-2 
can both homodimerize  and  heterodimerize  with  other  members  of  the  EGFR  
family  and activates a range of signal transduction pathways48. 
HER2/neu gene was first identified in rat neuroblastoma cell lines by Schubert 
et al in 197449. The relationship of HER2/neu with breast cancer was first identified 
in 1987 by Vijver et al50. 
Almasri et al in 2005 studied 91 cases and concluded that HER2/neu is 
overexpressed in 24% of cases of  breast carcinomas7. 
Rashed et al in 2007 studied 50 cases and concluded that HER2/neu is 
22 
  
overexpressed in 26% of cases of breast carcinomas51. 
Ayadi et al in 2008 studied 155 cases and concluded that HER2/neu is 
overexpressed in 18.1% of cases of breast carcinomas52. 
Azizun-nisa et al in 2008 studied 150 cases and concluded that HER2/neu is 
overexpressed in 24.7% of cases of breast carcinomas and concluded that 
Her2/neu over expression is seen with increasing tumour size and grade53. 
Mudduwwa et al in 2009 studied 151 cases and concluded that HER2/neu is 
overexpressed in 19.1% of cases of breast carcinomas54. 
Ambroise et al in 2011 studied 321 cases and concluded that HER2/neu is 
overexpressed in 27% of cases of breast carcinomas55. 
Ahmed et al in 2011 studied 137 cases and concluded that HER2/neu is 
overexpressed in 30.6% of cases of breast carcinomas55. 
Wolff et al in 2007 reviewed the literature and concluded that HER2/neu is 
overexpressed in 18% to 20% of cases of breast carcinoma11. 
Valérie Pawlowski et al in 2007 studied 365 cases and confirmed that 
HER2/neu expression is a marker of tumour aggressiveness in breast cancer56. 
Shinichi Tsutsui et al in 2002 followed-up 698 cases of carcinoma breast for 
54 months and concluded that HER2/neu positivity is associated with worse 
prognosis (higher rate of recurrence and mortality)57. 
Tatjana Ivkovic et al in 2007 studied 120 cases and found a statistically 
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significant correlation between HER2/neu protein overexpression and large tumour 
size, high histological grade and increased proliferative index58. 
Alfred  Carr et al in 2000 did a follow up study of 190 cases of carcinoma 
breast and concluded that HER2/neu oncogene is an independent prognostic indicator 
in subset of breast cancers that are at high risk of early recurrence, regardless of 
tumour grade, estrogen/progesterone receptor status and lymph node status. Patients 
amplifying the HER2/neu oncogene have a shorter disease-free survival than patients 
without the oncogene59. 
A multivariate analysis of 314 cases by Amanda H. McCann et al in 2000 
indicated that the HER2/neu oncoprotein was an independent prognostic indicator for 
overall survival in breast carcinoma patients60. 
DJ Slamon et al studied 189 cases in 1987 and concluded that HER2/neu has 
greater prognostic value than most currently used prognostic factors including ER, 
PR status9.  The  erbB-  2  status  was  superior  to  ER  as  a  prognostic  factor  in  
breast carcinoma as studied by Heikki et al in 200361. 
There are various methods of testing HER2/neu expression. IHC and Western 
blot are used to detect protein overexpression. Southern blot, PCR (Polymerase 
Chain Reaction), FISH (fluorescence in- situ hybridization) and CISH (chromogenic 
in- situ hybridization) are used for gene amplification and Northern blot for 
mRNA62. 
Selvarajan et al63 studied 41 cases in 2004 and Benöhr P et al64 studied 
15 cases in 2005 and concluded that HER2/neu status can be reliably assessed by 
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IHC technique if adequate quality control is assured. High level of concordance 
between FISH and IHC results (91%, P < .001) was seen12. 
Rani James et al in 2011 studied 207 cases and concluded that HER2/neu 
positive cancers exhibit resistance to tamoxifen but not to aromatase inhibitors 
or ovarian ablation (medical or surgical) 10. Similar conclusions were obtained by 
Love et al in 2003 by analysing 282 cases65. HER2/neu positivity is associated with 
relative resistance to non anthracycline nontaxane containing chemotherapy and 
responds  to anthracycline treatment. Trastuzumab, a humanized monoclonal 
antibody, improves response rates, time to progression and survival when used 
alone or in combination with chemotherapy and decreases the recurrence by 33%11. 
Moradi et al in 2008 studied 339 cases of breast cancer and concluded that 
HER2/neu over expression is significantly associated with higher tumour grade 
but not with stage66. 
Ludovini et al in 2007 found significant association of Her2/neu with high 
histological grade and concluded that Her2/neu is an independent predictive factor 
for shorter overall survival and disease free survival in invasive primary breast 
cancer. There was no statistically significant association with menopausal status, 
histological tumour type, tumour size, stage and lymph node involvement67. 
Lovekin et al in 1991 studied 782 patients and found that Her2/neu expression is 
associated with poorer prognosis68. 
Al- Moundhri et al in 2003 studied 72 cases and found no significant 
association of er2/neu with patient age, tumour size, tumour grade and lymph 
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node involvement69. 
Several techniques are available for the genetic testing of Her2/neu 
amplification. FISH is a reliable method. Semiquantitative measurement using IHC 
for the Her2/neu membrane receptor protein can also accurately predict gene 
amplification. FISH for Her2/neu has a higher failure rate and reagent cost than IHC, 
and it takes longer to carry out and interpret than IHC12. 
 
GUIDELINES FOR HER2/NEU TESTING ACCORDING TO ASCO-CAP 
GUIDELINES, 2007 TO 201111 
Specimen Handling Considerations for Her2/neu 
  The time duration from tissue removal to fixation (cold ischemic time)  should be 
short (ideally less than an hour). 
  Fixation time: It is the time when tissue is placed in fixative to time alcohol  is 
introduced on the tissue processor (includes the time to grossing and the time the 
cassettes in formalin are loaded on the tissue processor). 
  The tissue bisection through the tumour should be done immediately before 
tissue is placed in neutral buffered formalin (NBF), especially if sample is 
obtained remotely. 
       Required fixation time: It is >6 to <72 hours in 10% NBF. 
Analytic requirements for Her2/neu testing 
  The  external  controls  should  be  used  with  each  batch,  including   weakly 
positive controls for each analyte. 
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  The internal acinar elements should be reviewed on each case if they are 
present: The normal breast epithelium should be negative for Her2/neu. 
  The control tissues should be stained as on slide controls with each test if 
possible. 
Quality assurance requirements for Her2/neu assay 
  All assays should be validated before offering the testing in the laboratory, 
using 40 known positive (including weakly positive) cases and 40 known negative 
cases. 
  The  assays  should  be  revalidated  if  any  major  modification  in  the  assay 
procedure is done, using the same number of cases. 
  Each assay run should be monitored with batch controls.  
 External proficiency testing should be engaged for assays. 
  External or internal laboratory accreditation should be engaged depending   on 
standards in the region. 
  Careful review and appropriate intervention should be conducted. 
  Assay should be verified when  minor  modifications occur,  using 20   known 
positive (including weakly positive) cases and 20 known negative cases. 
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Interpretation guidelines 
Her2/neu IHC category of 3+ has been refined to assure that 95% would be 
FISH amplified if tested; 30% of cells must show homogeneous dark circumferential 
staining (chicken-wire pattern). 
Her2/neu FISH must be scored on the area of tumour defined by the 
pathologist. If IHC is performed, FISH should be scored in the area of highest 
IHC staining. 
Exercise caution in interpreting Her2/neu IHC when the following apply 
 Non- formalin fixatives (alcohol-based fixatives used for FNA) 
 Excessive delay from collection to fixation 
 Overfixed tissue –– Friday cases (>48–72 hours in formalin) 
 Inadequately fixed tissue (<6–8 hours NBF) 
 Excessive artifacts- edge, crush, disruption, necrosis 
 Decalcified blocks 
 Overexpression in benign elements 
Final reporting considerations for Her2/neu testing 
  Her2/neu is more likely in high-grade and poorly differentiated tumours. 
  Low-grade  tumours  typically  are  ER/PR  positive  and   Her2/neu   negative, 
including the following: 
 Classic infiltrating lobular carcinoma 
 Mucinous carcinoma 
 Tubular carcinoma 
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 A test result that does not fit the histological picture suggests the following: 
 The assay may be invalid 
 Repeat testing may be indicated. 
Molecular markers of future prospects43 
  The evaluation of DNA, RNA, and protein expression using the modern   tools of 
molecular biology, such as laser capture microdissection will greatly enhance our 
understanding of breast tumourigenesis and may even serve to redefine what 
constitutes “normal”. 
  For  example,  a  number  of  studies  have  shown  that  histologically  normal 
TDLUs can exhibit an abnormal genotype, characterized by loss of heterozygosity or 
allelic imbalance at various chromosomal loci. 
  However, the significance of these genetic alterations in histologically  normal 
breast tissue remains to be determined. 
  Studies of normal breast tissue using these techniques will also help define the 
presence and nature of progenitor cells or stem cells and their role in breast 
development and carcinogenesis as well as patterns of gene and protein expression 
that distinguish normal from abnormal breast tissue and cells. 
p53, Akt kinase, carbonic anhydrase IX, COX-2, e-cadherin, tumour DNA 
ploidy, hsp27, ps2, cathepsin D, metallothionein, VEGF, TGF beta, placental growth 
factor, hepatocyte growth factor, pleiotropin, PDGF, cyclin E are the ongoing 
research markers in carcinoma breast. 
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 Steps in modified radical mastectomy 
1. Patient in supine position with elevated right hemithorax. 
2. Parts painted and draped. 
3. Incision is made    according   to the   location of   tumor so  that tumor is included 
within the incision. 
4. Skin flaps raised above upto subclavius muscle, medially upto sternum,    laterally 
upto anterior margin of lattisimus   dorsi,     inferiorly upto 3 to 4cm from the inferior 
mammary fold. 
5.  Breast parenchyma and  pectoralis major fascia elevated from   pectoralis    major 
muscle. 
6. Level I,II,III  group of  axillary lymph        nodes   is    removed depending on  the 
involvement. 
7. Axillary vein, thoracodorsal neurovascular bundle  nerve to serratus anterior    and 
medial pectoral nerve is preserved.  
8. Saline wash should be given. 
9. Wound closed in layers. 
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 Figure-1: Showing intraoperative picture of modified radical mastectomy where 
axillary vein, thoracodoral neurovascular bundle, nerve to serratus anterior are 
preserved. Pectoralis major and minor muscles are retracted. 
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Methodology 
  
METHODOLOGY 
           Patients diagnosed as carcinoma breast, admitted in Department of General 
surgery,Govt. Royapettah Hospital during the period from November 2014 to august  
2015 were studied. 
Clinical data were obtained from patients‟ history, clinical examination, 
hospital records and requisition forms received in the department. The specimens 
were sent to the pathology department and  subjected to adequate fixation using  10% 
NBF. After adequate fixation, examination of the specimen for gross details 
according to the protocol for the examination of specimens of patients with invasive 
carcinoma of breast would  be done. Then representative tissue bits  subjected for 
routine processing and paraffin embedding. Three to four micron thick sections taken 
from paraffin embedded blocks. These sections  routinely stained with haematoxylin 
and eosin (H & E) and  examined noting the findings as per proforma. 
 
Procedure for H & E staining 
 Deparaffinise in xylene – 2 changes – 5 minutes each.  
 Wash in absolute alcohol – 1 change – 3 minutes. 
 Wash in water for 3-5 minutes. 
 Stain with haematoxylin for 5 minutes. 
 Wash in water for bluing for 3-5 minutes.     
 Dip in acid alcohol – 1dip 
 Wash in water for 3-5 minutes. 
 Stain with eosin for 1 – 2 dips. 
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 Wash in water for 1-2 dips.  
 Dip in alcohol – 1dip. 
 Blot, dry and mount in DPX. 
           The tumours were typed according to the WHO classification system.  The 
Nottingham modification of Bloom Richardson grading system was used   for grading 
(Table 1). 
Table – 1 : Histological grading using NSBR system 
Criteria Score 1 Score 2 Score 3 
Tubule formation >75% of tumour 10-75% of tumour <10% tumour 
Nuclear 
pleomorphism 
Minimal variation 
in size and shape 
of nuclei 
Moderate variation 
an size and shape 
of nuclei 
Marked variation 
in size and shape 
of nuclei 
Mitotic count/10 HPF 
(diameter 0.44 mm) 
 
0-5 
 
6-10 
 
>11 
 
Grade Score 
Grade 1 3-5 
Grade 2 6-7 
Grade 3 8-9 
 
Grade 1 carcinoma includes tumours with combined scores of 3- 5; grade 2 
includes scores of 6 and 7; and grade 3 includes tumours with the scores of 8 and 9. 
Each case was assessed considering important clinicopathological prognostic 
parameters like size of the tumour, histological grade, presence of necrosis, 
lymphovascular invasion, involvement of surgical margins, fibrosis, stromal 
reaction, involvement of the skin in the form of nipple and areola/Pagetoid spread 
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and metastases in the axillary lymph nodes. 
The grading of mitosis was done in all the cases and was divided into 3 grades. 
The cases with 0- 5 mitoses were placed in grade 1, 6- 10 mitoses in grade 2 and >  11 
mitoses in grade 3 (Table 2). 
                                     Table – 2 : Table showing grading of mitosis 
Mitosis grade Number of mitoses 
Grade 1 0- 5 
Grade 2 6- 10 
Grade 3 > 11 
Lymph node staging was done in the 50 cases of carcinoma breast studied. 
The cases with no lymph nodes were placed in stage N0, 1- 3 lymph nodes with 
metastases were placed in stage N1, 4- 9 lymph nodes with metastases in stage N2 
and > 10 lymph nodes with metastases in stage N3. 
                           Table – 3 : Table showing staging of lymph nodes 
Lymph node staging 
Number of positive 
lymph nodes Stage N0 0 
Stage N1 1-3 
Stage N2 4- 9 
Stage N3 10 or more. 
 
The Nottingham Prognostic Index (NPI) was calculated as follows17: 
NPI = lymph node stage (1-3) + grade (1-3) + maximum diameter (cm x 0.2). 
The scoring of lymph node stage in NPI is as follows: No metastases in the lymph 
node- Score 1; metastases in 1- 3 lymph nodes- Score 2 and metastases in > 4 lymph 
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nodes- Score 3. The histologic grading used is the NSBR grading (Table-1). 
After calculation of the NPI score, all the 50 cases of carcinoma breast were 
divided into six prognostic groups (Table 4). 
           Table – 4 : Table showing Nottingham Prognostic Index (NPI) groups 
Prognostic group NPI Score 
Excellent prognostic group (EPG) 2.08 – 2.4 
Good prognostic group (GPG) 2.42 – 3.4 
Moderate prognostic group I(MPG I) 3.42 – 4.4 
Moderate prognostic group II (MPG II) 4.42 – 5.4 
Poor prognostic group (PPG) 5.42 – 6.4 
Very poor prognostic group (VPG) 6.42 – 6.8 
 
All the 50 cases were subjected to IHC study for Her2/neu from the 
representative areas of the tumour. The polymer based IHC kit of BioGenex RTU 
was used. 
Procedure of IHC staining for Her2/neu staining 
Cut the sections at approximately 2-3 microns thick.  
Float them on to positive charged slides. 
Incubate for 37º C for one day and further incubate at 58ºC for over- night.  
Two changes of xylene of 15 minutes each for deparaffinization. 
Two changes of absolute alcohol of 1 minute each for rehydration.  
One change of 90% alcohol of 1 minute for rehydration. 
 One change of 70% alcohol of 1 minute for rehydration. 
Wash in tap water for 10 minutes. 
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Rinse in distilled water for 5 minutes. 
Antigen Retrieval by Heat using pressure cooker for 4 whistles  
Cooling of the sections to room temperature. 
Rinse in distilled water for 5 minutes. 
Wash in TBS buffer (pH•7.6) two times for 5 minutes each. 
Treatment  with  peroxide  block  for  10-  15  minutes  to  block  endogenous 
peroxidase enzyme. 
Wash in TBS buffer (pH•7.6) three times for 5 minutes each. 
Treatment with power block for 15 minutes to block   non  specific   reaction with the 
other tissue antigens. 
Drain the excess power block. 
Treatment with primary antibody for    Her2/neu   for 30- 60 minutes to    identify the 
tumour markers by antigen- antibody reaction. 
Wash in TBS buffer (pH-7.6) three times for 5 minutes each. 
Treatment with SS enhancer for 20 minutes to enhance the reaction 
Wash in TBS buffer (pH-7.6) three times for 5 minutes each. 
Treatment   with SS Polymer  (secondary antibody) for 30  minutes  to elongate chain 
and also to label the enzyme. 
Wash  in TBS buffer (pH - 7.6)  three  times  for  5 minutes each  to wash unbounded 
antibodies. 
Treatment with DAB working solution for 5-8    minutes to give brown colour    to the 
antigens. 
Wash in TBS buffer (pH•7.6) three times for 5 minutes each.  
Wash in tap water for 5 minutes. 
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Counter stain with Harris haematoxylin for 1 minute. 
 Wash in tap water for 5 minutes to wash excess stain. 
Two changes of xylene of 15 minutes each for deparaffinization.   
        Two changes of absolute alcohol of 1 minute each for dehydration.     
        One change of 90% alcohol of 2 minutes for dehydration. 
        Two changes of absolute alcohol of 2 minutes for dehydration.  
      Clearing with xylene for 2 minutes. Mount with DPX. 
Preparation of reagents 
Antigen Retrieval Buffer Tris 
EDTA Buffer: pH – 9.0 
Tris Buffer - 6.05  grams 
EDTA - 0.744 grams 
Dissolve in 1000 ml of distilled water. 
1) Wash Buffer 
Tris Buffered Saline: pH– 7.6 
Tris buffer - 0.6 grams 
NaCl - 8 grams Dissolve 
in 1000ml of Distilled water. Adjust pH with 
1N Hcl. 
Precautions to be taken while testing 
 Do not allow sections to dry at any stage of the staining procedure. Carry    out     the 
steps of incubation with antibody at 37ºC. Use appropriate controls for each antibody 
tested. 
       Table – 5 : Table showing assessment of Her2/neu protein overexpression 
 
Staining pattern 
 
Score 
 
Her2/neu protein 
overexpression 
assessment 
No staining is observed or membrane staining is 
observed in less than 10% of the tumour cells 0 Negative 
A faint/barely perceptible membrane staining is 
detected in more than 10% of the tumour cells. The 
cells are only stained in part of their membrane 
 
1+ 
 
Negative 
A weak to moderate complete membrane staining is 
observed in more than 10% of the tumour cells 2+ Weakly positive 
A strong complete membrane staining is observed in 
more than 30% (formerly 10%) of the tumour cells 
 
3+ 
 
Strongly positive 
 
A score of 2+ and 3+ Her2/neu were considered positive for immunostaining. 
Correlation of Her2/neu expression with above mentioned important 
clinicopathological prognostic parameters and with NPI was done. 
Plan of data analysis 
The collected data was entered in Excel sheet and analysed using Epiinfo 
software and the descriptive statistics, Chi-square test, Student‟s t-test, 
McNemar‟s test and other applicable statistical tests were applied for the data as 
applicable. The p value of < 0.05 was considered statistically significant. 
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Results 
  
RESULTS 
 
In the present study, a total number of 50 cases of carcinoma breast were 
evaluated during this retrospective and prospective study conducted from November 
2014 to august 2015 in the department of general surgery,govt. royapettah hospital. 
History 
 In the present study, the age of the patients with     carcinoma     breast  ranged 
from 20 to 80 years. Majority of the patients (70%) were in the age group    of 40 to 
59 years (Table 6, Figure 1).  
Table – 6 : Table showing presenting history of patients with carcinoma breast 
Age (years) Number (%) 
< 39 6(12) 
40 – 59 35(70) 
> 60 9(18) 
Pain  
Absent 41(82) 
Present 9(18) 
Nipple Discharge  
Absent 45(90) 
Present 5(10) 
Menopause  
Premenopausal 14(28) 
Postmenopausal 36(72) 
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Figure – 2 : Chart showing age ditribution of patients with carcinoma breast 
 
 
 
 Figure-3: Chart showing pain in patients with carcinoma breast 
 
 
 
                                                           42 
 
0
5
10
15
20
25
30
35
40
20-39 40-59 60-80
n
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Age in years
Absent
82%
Present
18%
Pain
 
 
 
  
     
  
 
  
Figure-4:Chart showing nipple discharge in patients with carcinoma breast 
 
 
Figure-5:Chart showing menopausal status of patients with carcinoma breast 
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In the present study, all the 50 (100%) cases presented with lump in the 
breast, 9(18%) cases with pain in addition to lump (Table 6,Figure 3)  and 5 (10%) 
cases presented with nipple discharge (Table 6, Figure 4). 
In the present study 36 (72%)  patients were in the premenopausal age group 
(Table 6, Figure 5). 
 
Family history 
In the present study, none of the cases had positive family history. 
Past history 
In the present study, none of the cases had past history of breast lesion. 
Breast feeding 
In the present study, 72% of the  patients were multiparous and all of them 
had breast fed. 
Clinical examination 
Table – 7 : Table showing the distribution of carcinoma breast according to 
location of the tumour 
 
Location of the tumour Number (%) 
UOQ 36 (72) 
Central 04 (08) 
Multiple 10 (20) 
Axillary tail lump 00 (00) 
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Figure – 6 : Chart showing the distribution of carcinoma breast according 
to location of the tumor 
 
 
On clinical examination, the tumour was in the upper outer quadrant (UOQ) in 
36 (72%) cases. In 4 (8%) cases the tumour was central in location and in 10 
(20%) cases the tumour was involving multiple quadrants (Table 7, Figure 6). 
GROSS EXAMINATION OF SPECIMEN 
All the specimens in the present study were modified radical mastectomy 
specimens. The relevant gross examination findings of the specimen were as follows 
Table – 8 : Table showing the distribution of carcinoma breast according to 
size  of the tumour 
Tumor  Size (cm) Number (%) 
< 2 4(8) 
2 - 5 32(64) 
≥ 5 14(28) 
0
5
10
15
20
25
30
35
40
UOQ Central Multiple Axillary tail
lump
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Quadrants
 
 
 
  
45 
  
                                                                       
Figure – 7 : Chart showing the distribution of carcinoma breast according to 
size  of the tumour 
 
 
 
In the present study of 50 cases of    carcinoma breast, the     size of the 
tumour     ranged  from 1.5 cm to 8 cms     considering the    largest   dimension of the 
tumour. In 4 (8%) cases the tumour size was < 2 cms, in 32 (64%) cases     the tumour 
size ranged from 2 to 5 cms, and  14 (28%)    cases had a     of tumour     size of > 5 
cms (Table 8, Figure 7) 
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Table – 9 : Table showing the histological grading of the cases using 
Nottingham modification of Scarff  Bloom Richardson (NSBR) system 
NSBR Grade Number (%) 
1 3(6) 
2                 45(90) 
3                  2(4) 
 
Figure – 8 : Chart showing the histological grading of the cases using 
Nottingham modification of Scarff Bloom Richardson (NSBR) system 
 
Of the 50 cases of invasive   carcinoma     breast studied, 3cases  (6%) were of 
grade 1, 45 (90%) cases were of grade 2 and 2 cases (4%)   belonged to grade 3 
(Table 9, Figure 8). 
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Table – 10 : Table showing  staging of lymph nodes 
Positive lymph node        Number(%) 
N0 24(48) 
N1 14(28) 
N2 8(16) 
N3 4(8) 
 
Figure-9:Chart showing staging of lymph nodes in carcinoma breast 
        
 
 
 
Of the 50 cases of carcinoma breast, 24 (48%) cases were of stage N0, followed 
by 14 (28%) cases of stage N1, 8 (16%) cases of stage N2 and 4 (8%) cases of stage N3 
(Table 10,Figure 9). 
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Table – 11 : Table showing the distribution of carcinoma breast according to 
Nottingham prognostic index (NPI) 
NPI group Number (%) 
EPG 2(4) 
GPG 8(16) 
MPG I                14(28) 
MPG II 16(32) 
PPG 9(18) 
VPG 1(2) 
Figure – 10 : Chart showing the distribution of carcinoma breast 
according to Nottingham prognostic index (NPI) 
 
 
The NPI in the 50 cases of carcinoma breast showed 2 (4%) cases in EPG, 
8(16%) cases in GPG, 14 (28%) in MPG I, 16 (32%) in MPG II, 9 (18%) cases 
in PPG and 1 (2%) in VPG groups (Table 11, Figure 10). 
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Immunohistochemistry 
Table – 12 : Table showing Her2/neu expression of the tumour 
Her2/neu expression Number (%) 
Negative                   36(72) 
Positive 14(28) 
 
 
Figure – 11 : Chart showing Her2/neu expression of the tumour 
 
 
 
The Her2/neu was expressed in 14 (28%) out of 50 cases of  carcinoma breast 
(Table 12, Figure 11) in the present study . 
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Association of Her2/neu with various clinicopathological and prognostic parameters 
Table – 13:  Table showing age distribution of carcinoma breast 
and its association with Her2/neu 
Age in 
years 
 
Number(%) 
  
HER2/neu Total P 
value 
Negative Positive   
20-39 
 
 
Number 4 2 6  
 
 
 
 
 
 
 
 
 
0.673 
% within 
Age in 
years 
66.7% 33.3% 100.0% 
% within 
HER2/neu 
11.1% 14.3% 12.0% 
40-59 
 
 
Number 26 11 37 
% within 
Age in 
years 
70.3% 29.7% 100.0% 
% within 
HER2/neu 
72.2% 78.6% 74.0% 
60-80 
 
 
Number 6 1 7 
% within 
Age in 
years 
85.7% 14.3% 100.0% 
% within 
HER2/neu 
16.7% 7.1% 14.0% 
Total Number 36 14 50 
% within 
Age in 
years 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
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Figure – 12 : Chart showing age distribution of carcinoma breast and its association 
with Her2/neu 
 
 
 Maximum Her2/neu positivity was seen in the age group of 40-59 years (78.6%) 
and the least Her2/neu positivity was seen between the age group of 60-80 years (7.1%) 
(Table 13, Figure 15 ). A statistically significant association of Her2/neu with age was 
not noted in the present study (p value = 0.673). 
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Table-14:Table  showing pain in patients with carcinoma breast and its association 
with Her2/neu 
Pain 
  
 Number(%) 
HER2/neu Total P value 
Negative Positive    
 
 
 
 
 
 
 
 
0.042 
 
 
Absent 
 
 
Count 32 9 41 
% within Pain 78.0% 22.0% 100.0% 
% within 
HER2/neu 88.9% 64.3% 82.0% 
 
 
 
Present 
 
 
Count 4 5 9 
% within Pain 44.4% 55.6% 100.0% 
% within 
HER2/neu 
11.1% 35.7% 18.0% 
 
Total 
Count 36 14 50 
% within Pain 72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
 
Figure-13:Chart showing pain in patients with carcinoma breast and its association 
with Her2/neu 
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Table-15:Table showing nipple discharge in patients with carcinoma breast and its 
association with Her2/neu 
Nipple 
dicharge 
 
 Number(%) 
HER2/neu    
Total 
P value 
Negative Positive  
 
 
 
 
 
 
 
.006 
 
 
Absent 
Count 35 10 45 
% within Nipple 
Discharge 
77.8% 22.2% 100.0% 
% within 
HER2/neu 
97.2% 71.4% 90.0% 
 
 
Present 
Count 1 4 5 
% within Nipple 
Discharge 
20.0% 80.0% 100.0% 
% within 
HER2/neu 
2.8% 28.6% 10.0% 
 
 
Total 
Count 36 14 50 
% within Nipple 
Discharge 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
 
 
Figure-14 : Chart showing nipple discharge in patients with carcinoma breast 
anditsassociation with Her2/neu
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Table – 16:  Table showing menopausal status of carcinoma breast and its 
correlation with Her2/neu 
Menopause 
  
 Number(%) 
HER2/neu Total P value 
Negative Positive    
 
 
 
 
 
 
 
0.449 
 
 
Not Attained 
  
  
Count 9 5 14 
% within 
Menopause 
64.3% 35.7% 100.0% 
% within 
HER2/neu 25.0% 35.7% 28.0% 
 
 
 
 
Attained 
  
  
Count 27 9 36 
% within 
Menopause 
75.0% 25.0% 100.0% 
% within 
HER2/neu 
75.0% 64.3% 72.0% 
Count 36 14 50 
% within 
Menopause 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
 
Figure – 15:  Chart showing menopausal status of carcinoma breast and its 
association with Her2/neu 
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In the present study majority of  patients (72%) were in the postmenopausal age 
group. Maximum Her2/neu positivity (64.3%) was seen in the post- menopausal age 
group (Table 16, Figure 15). No statistically significant association of Her2/neu with 
menopausal status was noted in the present study (p value = 0.449). 
Table – 17 : Table showing size of the tumour and its association 
with Her2/ neu 
 
Tumor 
size 
  
 Number(%) 
HER2/neu Total 
  
P value 
Negative Positive  
 
 
 
 
 
 
 
    
0.374 
< 2 
  
  
Count 2 2 4 
% within 
Tumor Size 
50.0% 50.0% 100.0% 
% within 
HER2/neu 
5.6% 14.3% 8.0% 
2-5 
  
  
Count 25 7 32 
% within 
Tumor Size 
78.1% 21.9% 100.0% 
% within 
HER2/neu 
69.4% 50.0% 64.0% 
>= 5 
  
  
Count 9 5 14 
% within 
Tumor Size 
64.3% 35.7% 100.0% 
% within 
HER2/neu 
25.0% 35.7% 28.0% 
Total Count 36 14 50 
% within 
Tumor Size 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
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Figure – 16 : Chart showing size of the tumour and its association with Her2/neu 
 
 
 
         Cases with the tumour size of <2 cms were 2 cases negative and 2 cases positive 
for Her2/ neu. The maximum Her2/neu positivity was seen in 7(50%)  with the tumour 
size between 2- 5 cms. Her 2/ neu was positive in 5 (35.7%) out of 14 cases with the 
tumour size > 5 cms (Table 17, Figure 16). No statistically significant association of 
Her2/neu with tumour size was noted in the present study (p value = 0.374). 
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Table -18: Table showing histological grading of tumour using Nottingham 
modification of Scarff Bloom Richardson system and its association with Her2/neu 
 
 
 
Grade 
  
Number(%) 
HER2/neu Total P value 
Negative Positive    
 
 
 
 
 
0.340 
 
1 
  
  
Count 3 0 3 
% within 
Grade 
100.0% .0% 100.0% 
% within 
HER2/neu 
8.3% .0% 6.0% 
2 
  
  
Count 31 14 45 
% within 
Grade 
68.9% 31.1% 100.0% 
% within 
HER2/neu 
86.1% 100.0% 90.0% 
3 
  
  
Count 2 0 2 
% within 
Grade 
100.0% .0% 100.0% 
% within 
HER2/neu 
5.6% .0% 4.0% 
Total Count 36 14 50 
% within 
Grade 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
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Figure - 17: Chart showing histological grading of tumour using Nottingham 
modification of Scarff Bloom Richardson system and its association with 
Her2/neu 
 
 
 
 
 
 
 
While correlating the over expression of Her2/neu with the histological grading, 
all cases (3 cases) of grade 1 tumours were negative for Her2/ neu, 68.9% (31 out  of 
45 cases) of grade 2 tumours and 100% ( 2 cases) of grade 3 tumours were negative  
for Her2/neu (Table 18, Figure 17). All cases of  Her2/neu positivity were seen only in 
grade 2.  No statistically significant association of Her2/neu with  histologic grade was 
noted in the present study (p value = 0.340). 
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Table – 19: Table showing Nottingham Prognostic Index (NPI) and its  
correlation with Her2/n 
NPI 
group Number(%) 
HER2/neu Total 
  
P value 
Negative Positive  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.235 
EPG Count 2 0 2 
  % within NPI 
group 
100.0% .0% 100.0% 
  % within 
HER2/neu 
5.6% .0% 4.0% 
GPG Count 6 2 8 
  % within NPI 
group 
75.0% 25.0% 100.0% 
  % within 
HER2/neu 
16.7% 14.3% 16.0% 
MPG I Count 12 2 14 
  % within NPI 
group 
85.7% 14.3% 100.0% 
  % within 
HER2/neu 
33.3% 14.3% 28.0% 
MPG II Count 9 7 16 
  % within NPI 
group 
56.3% 43.8% 100.0% 
  % within 
HER2/neu 
25.0% 50.0% 32.0% 
PPG Count 7 2 9 
  % within NPI 
group 
77.8% 22.2% 100.0% 
  % within 
HER2/neu 
19.4% 14.3% 18.0% 
VPG Count 0 1 1 
  % within NPI 
group 
.0% 100.0% 100.0% 
  % within 
HER2/neu 
.0% 7.1% 2.0% 
Total Count 36 14 50 
% within NPI 
group 
72.0% 28.0% 100.0% 
% within 
HER2/neu 
100.0% 100.0% 100.0% 
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Figure – 18: Chart showing Nottingham Prognostic Index (NPI) and its 
correlation with Her2/neu 
 
 
All the cases belonging to EPG were negative for Her2/ neu. The 
positivity of Her2/neu was seen in 2 (25%) cases of GPG, 2 (14.3%) cases of 
MPG I, 7 (43.8%) cases of MPG II, 2 (22.2%) cases of PPG and 1 (100%) 
cases of VPG prognostic groups (Table 19, Figure 18). No statistically 
significant association of Her2/neu with NPI was noted in the present study (p 
value = 0.235). 
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Table – 20 : Table showing Lymph node staging and its association with Her2/ neu 
 
Lymph Node 
Metastasis 
 Number(%) HER2/neu Total 
  
P value 
  Negative Positive  
 
 
 
 
 
 
 
 
 
 
 
 
 
0.012 
N0 Count 22 2 24 
  % within Lymph 
Node Metastasis 
91.7% 8.3% 100.0% 
  % within HER2/neu 61.1% 14.3% 48.0% 
N1 Count 6 8 14 
  % within Lymph 
Node Metastasis 
42.9% 57.1% 100.0% 
  % within HER2/neu 16.7% 57.1% 28.0% 
N2 Count 5 3 8 
  % within Lymph 
Node Metastasis 
62.5% 37.5% 100.0% 
  % within HER2/neu 13.9% 21.4% 16.0% 
N3 Count 3 1 4 
  % within Lymph 
Node Metastasis 
75.0% 25.0% 100.0% 
  % within HER2/neu 8.3% 7.1% 8.0% 
Total Count 36 14 50 
% within Lymph 
Node Metastasis 
72.0% 28.0% 100.0% 
% within HER2/neu 100.0% 100.0% 100.0% 
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 Figure – 19 : Chart showing Lymph  node staging and 
its correlation with Her2/neu 
 
 
 
Out of 50 cases of carcinoma breast, 24 (48%) showed no lymph node 
metastases in which only 2 (8.3%) out of 24 cases showed positivity for 
Her2/neu in the primary breast tumour. 
The other 26 cases (52%) showed lymph node metastases with 14 
(28%), 8 (16%) and 4 (8%) cases in stage N1, N2 and N3 respectively. Her2/neu 
was positive in 8(57.1%), 3(37.5%), and 1(25%) cases of stage N1, N2 and N3 
respectively (Table- 20, Figure 19).  Statistically significant association of 
Her2/neu with lymph node staging was noted in the present study (p value = 
0.012). 
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Figure – 20 : Mastectomy specimen – Cut section showing gray white 
tumour of more than 5 cms 
 
 
 
Figure – 21 : Microphotograph of Infiltrating duct carcinoma, NOS type 
(H & E, X50) 
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Figure – 22 : Papillary carcinoma (H & E, X 50) 
 
 
 
 
Figure – 24: Strong, complete membranous immunostaining (score of 3+) with 
HER-2/neu antibody in more than 10% of IDC cells (DAB, ×400) 
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Figure – 25: Weak, moderately complete membranous HER-2/neu 
immunostaining (score of 2+) in IDC cells (DAB, ×400) 
 
 
 
 
 
Figure – 26: Faint, incomplete membranous HER-2/neu immunostaining 
(score of 1+) in IDC cells (DAB, ×400). 
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Discussion 
  
DISCUSSION 
In our study of 50 cases of breast carcinoma, majority of the patients were 
between the age group of 40- 59 years. This finding is similar to studies of Mansour Al- 
Moundhri et al69 (49.6 years), Azizun- Nisa et al53 (48.3 years), Moradi- Marjaneh M et 
al66 (47.4 years), and Lobna Ayadi et al52 (51.5 years). 
 In our study carcinoma breast was more     common in      postmenopausal age 
group (72%)  not similar to studies by Mona M Rashed et al51 (70%)    and    Moradi- 
Marjaneh M et al66 (58.3%). However in the study by Mansour Al- Moundhri et al69  
only 59.7% of patients were in the postmenopausal age group. 
In the present study majority of the cases (64%) had the tumour size ranging 
from 2- 5 cms, followed by 14 (28%) cases of tumour size of > 5 cms and 4 (8%) 
cases of < 2 cms. In the study by Azizun- Nisa et al53  also, 52.7% of tumour 
were between 2-5 cms and 35.3% were > 5 cms. The study of Mona M Rashed et 
al51     also 54% of cases had tumour size of 2-5 cms while 36% had a tumour size of 
> 5 cms. 
Among the 50 cases of invasive carcinoma breast in our study, majority of the 
cases (49 cases, 98%) were of infiltrating      ductal carcinoma,   NOS type and 1 case 
(2%) was invasive papillary carcinoma. 
  Similarly, in the study by Farid Saleh et al70 the most common histologic 
subtype was infiltrating ductal carcinoma, NOS type (98%)  and 2% of invasive 
papillary carcinoma. In the study by Lobna Ayadi et al52 also, 84% were of 
infiltrating ductal carcinoma type and 16% were of non- ductal type. 
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Table – 21 : Table showing comparison of NSBR grade between various studies 
 
 
NSBR 
Grade 
Mona ashed 
et al51 2007 
Saleh F et 
al70  2007 
Azizun- 
Nisa53 et al 
2008 
Moradi M 
et al66 2008 
Our study 
2015 
No. (%) No. (%) No. (%) No. (%) No. (%) 
1. 05 (10%) 17(10.2%) 10 (6.7%) 28 (10.5) 3 (6 %) 
2. 27 (54%) 84(50.6%) 83 (55.3%) 156 (58.6) 45 (90 %) 
3. 18 (36%) 65(39.2%) 57 (38%) 82 (30.8) 2 (4 %) 
 
Of the 50 cases of invasive carcinoma breast studied, majority of the cases (45 
cases,  90%)  were  of  grade  2,  followed  by 3  cases  (6%)  of  grade  1.     The least 
number of cases (4%) were of grade 3 (Table -9 , 18, Figure - 17).            Similar 
findings were noted in the studies of Mona Rashed et al51 (2007), Saleh F et al 
(2007)70, Azizun- Nisa et al53 (2008) and Moradi M et al66 (2008) were majority in 
grade 2. 
 
Of the 50 cases of carcinoma breast, majority (24 cases, 48%) were of stage 
N0, followed by 14 (28%) cases of stage N1, 8 (16%) cases of stage N2 and 4 (8%) 
cases of stage N3 (Table-10, Figure- 9). In contrast, Mohammad Naeem et al71 
found that majority of the tumours belonged to N3 stage (41.7%) followed by N2 
(37.5%), N0 (12.5%) and N1 (8.3%). 
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Table – 22 : Table showing comparison of NPI between various studies 
 
Nottingham 
prognostic index 
(NPI) 
Blamey et al17 
1980 (892 cases) 
Blamey et 
al17 1990 
(2238 
cases) 
 
Our study 2015 
(50 cases) 
EPG 12% 15% 04% 
GPG 19% 21% 16% 
MPG I 29% 28% 28% 
MPG II 24% 22% 32% 
PPG 11% 10% 18% 
VPG 05% 04% 2% 
 
The NPI in the 50 cases of carcinoma breast showed that most of the patients 
were in the moderate prognostic group II (32%) . Out of 50 cases, only 2 (4%) 
and 1 (2%) cases were in excellent and  very poor prognostic groups respectively 
(Table-11, Figure- 10). In comparison, the study by Blamey et al17  in 1980 and 
1990 showed that majority of the cases were in MPG I. 
The Her2/neu was expressed in 14 (28%) out of 50 cases of carcinoma breast 
in the present study. The Her2/neu expression in various studies varied from 15% 
to 93.4% as shown in table 12. 
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Table – 23: Table showing comparison of incidence of Her2/neu expression 
 
 
Study (year) 
Incidence of Her2/neu expression 
Positive/total (%) 
Lovekin C et al68 (1991) 70/480 (15.0) 
Mona Rashed et al51 (2007) 13/50 (26.0) 
Saleh et al70 (2007) 155/166  (93.4) 
Tatjana Ivkovic et al58 (2007) 23/120 (20.0) 
Moradi M et al66 (2008) 165/319  (51.7) 
Azizun- Nisa et al53 (2008) 56/150 (37.4) 
Ayadi et al52 ( 2008) 28/155 (18.1) 
Vaidyanathan K K et al48 (2010) 159/368  (43.2) 
Ambroise et al3 (2011) 87/321 (27.1) 
Resit Dogan K et al72 (2011) 12/59 (20.3) 
Ahmed et al55 (2011) 42/137 (30.6) 
Huang et al47 (2012) 241/1362 (17.7) 
Our study (2015) 14/50 (28.0) 
 
Maximum Her2/neu positivity was seen in the age group of 40-59 years 
(78.6%). No statistically significant association of Her2/neu with age was noted in 
the present study (p value = 0.673). 
The results in our study showed that Her2/neu expression increased with age. 
A study by Al- Moundhri et al69 (2003) also showed similar results where 12 out of 
13 patients with positivity for Her2/neu were > 40 years of age. However many 
other studies showed increased Her2/neu expression in younger age group (Almasri 
et al7 [2005], Farid Saleh et al70 [2007] and Moses Ambroise et al3 [2011]). Studies 
byH J et al47 (2005), Mona Rashed et al51 (2007) and Vaidyanathan K K et al48 
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(2010) showed no correlation of Her2/neu expression with age. Patients in post 
menopausal age group showed more Her2/neu positivity (64.3%) than pre 
menopausal age group patients (35.7%). No statistically significant association of 
Her2/neu with menopausal status was noted in the present study (p value = 0.449). 
Similarly studies by Rashed M et al51 (2007) and Vaidyanathan K K48 et al48  
(2010)  showed  no  statistically significant correlation  of  Her2/neu expression with 
menopausal status. 
Survival analysis done by Vaidyanathan K K et al48 (2010) revealed that 
Her2/neu overexpression is poor prognostic indicator. At 40 months of follow 
up 83.8% of Her2/neu negative individuals had disease free survival whereas only 
46.1 % of Her2/neu positive individuals had disease free survival. 
Table – 24: Table showing comparison of Her2/neu expression 
with tumour size 
 
Size Mona 
Rashed et 
al51  2007 
(%) 
Saleh et 
al70 
2007(%) 
Tatjana et 
al58 2007 
(%) 
Azizun- Nisa 
et al53 2008 
(%) 
Our 
study 
2015 (%) 
≤ 2 cms 00.0 28.0 06.3 22.2 14.3 
2- 5cms 08.0 84.3 29.5 21.5 50.0 
> 5 cms 38.0 92.3 46.2 30.2 35.7 
 p = 0.0115 p   < 0.005 p = 0.001 p   < 0.001 p = 0.374 
 
Tumour size is one of the most useful predictors of behaviour of breast 
carcinoma. In the present study, while correlating the Her2/neu positivity with  the 
size of the tumour, 2 cases with tumour size < 2 cms were positive for Her2/ neu. 
         72 
  
Majority of Her2/neu positivity was seen in with the tumour size between 2- 5 
cms (50%), followed by 35.7% Her2/neu positivity was seen with the tumour size 
> 5 cms (Table 17). However no statistically significant association of Her2/neu with 
tumour size was noted in the present study (p value = 0.374). 
The higher rates of Her2/neu overexpression in larger tumour size have also 
been documented in some studies as depicted in Table 28 and all of them showed 
a statistically significant association of Her2/neu with tumour size. 
While correlating the over expression of Her2/neu with the histologic 
subtype, all the 14 positive cases of Her2/neu was seen in infiltrating ductal 
carcinoma, NOS type. None of the other types showed HER-2 positivity. 
Similarly, 90.9% and 71.7% of infiltrating duct carcinoma (NOS type) were 
positive for Her2/neu in the studies done by Naeem et  al71  (2008) and Saleh F 
et al70  (2007). In contrast, the study by Ayadi et al52  (2008) showed 16.8% and 
25% Her2/neu positivity in ductal and non ductal carcinomas respectively. 
Table – 25: Table showing relationship between histologic grades 
and Her2/neu positivity 
Study 
Grade 1(%) Grade 2(%) Grade 3(%) p value 
Lovekin et al68 (1991) 03.0 11.0 21.0 <0.0001 
Mona Rashed et al51 (2007) 00.0 04.0 22 0.00001 
Saleh et al70 (2007) 05.9 92.9 87.7 < 0.005 
Tatjana et al58 (2007) 00.0 18.1 47.6 < 0.0001 
Moradi M M et al66 (2007) 46.0 46.6 62.0 0.016 
Azizun- Nisa53  et al (2008) 00.0 22.9 31.6 < 0.001 
Naeem M et al71 (2008) 00.0 18.2 81.8 >0.05 
Resit Dogan et al72 (2011) 00.0 23.1 27.3 0.184 
Our study (2015) 00.0 100.0 00.0 0.340 
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While correlating the over expression of Her2/neu with the histological 
grading, all the Her2/neu positive tumors were grade 2 tumors.  This suggests that 
the percentage of  expression of Her2/neu is more frequent in higher grade breast 
carcinomas than in lower grade. The studies by various authors shown in the (Table 
18) also showed similar results. 
No statistically significant association of Her2/neu with histologic grade was 
noted in the present study (p value = 0.102) similar to the studies by Naeem et al71 
(2008) and Resit Dogan et al72 (2011). Unlike our study, most of the studies by 
Lovekin et al68 (1991), Mona Rashed et al51 (2007), Saleh et al70 (2007), Tatjana 
et  al58 (2007), Moradi M M et al66 (2007) and Azizun- Nisa et al53 (2008) showed 
statistically significant association of Her2/neu with histologic grade.  
The correlation of Her2/neu with NPI in the 50 cases of carcinoma breast 
showed that most of the Her2/neu positive cases were seen in the moderate 
prognostic group II (50%). None of the cases in excellent group were positive for 
Her2/neu (Table-19, Figure- 18). No statistically significant association of Her2/neu 
with NPI was noted in the present study (p value = 0.235). 
The Nottingham Prognostic Index (NPI) is a well established and widely used 
method of predicting survival of operable primary breast cancer. The NPI is 
compiled from grade, size and lymph node status of the primary tumour. No studies 
correlating the NPI with Her2/neu status with best of our knowledge has been 
done so far. Further studies have to be done to determine the significance of 
correlation of Her2/neu with NPI and to find if this correlation has an advantage 
over NPI alone in predicting the survival rate of breast carcinoma patients. 
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Of the 14 Her2/neu positive cases in primary tumour of our study, 
12(85.7%) cases showed metastases in the lymph nodes and only 2(14.3%) cases 
showed no metastases in the lymph nodes suggesting that Her2/neu positivity 
increases the risk of metastases. Statistically significant association of Her2/neu  
with lymph node staging was noted in the present study (p value = 0.012). 
In the studies by Tatjana et al58 (2007), Moradi M M et al66 (2007), Azizun- 
Nisa et al53 (2008) and Naeem M et al71 (2008) also showed increased expression 
of Her2/neu in cases with lymph node involvement and only study Azizun- Nisa 
et al53 (2008) had a statistically significant correlation (Table 26). 
Table – 26: Table showing Her2/neu expression in relation to lymph 
node involvement 
 
Study Lymph node 
negative (%) 
Lymph node 
positive (%) 
 
p value 
Tatjana et al58 (2007) 47.8 52.2 >0.05 
Moradi M M66  et al (2007) 23.1 76.9 >0.05 
Azizun- Nisa53  et al (2008) 10.7 89.3 <0.001 
Naeem M71  et al (2008) 09.0 91.0 >0.05 
Al- Moundhri et al69 (2003) 61.5 38.5 0.8 
Our study (2015) 14.3 85.7 0.012 
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 CONCLUSION 
 
Her2/neu overexpression participates in the pathogenesis of breast 
carcinomas. They are indicators of poor prognosis in breast carcinoma and usually 
correlated with histological grade and stage components of breast carcinomas. 
 Our study evaluated Her2/neu positive immunoreactivity and correlated with 
established prognostic factors like clinicopathological parameters, NSBR grade 
and NPI in 50 cases of carcinoma breast. 
 According to the data of our study, a significant statistical       association was 
found between Her2/neu and presenting symptoms such as pain and nipple 
discharge, and lymph node status. 
 Although no significant statistical association of Her2/neu with tumour size 
and  grade  was seen, Her2/neu expression was more frequent in cases with 
tumour size more than 2 cms and  higher grades. This perhaps is attributed to the 
study of limited number of cases. 
 No statistical correlation of Her2/neu with menopausal status and NPI group 
was noted. Her2/neu positive immunoreactivity was more frequently seen in 
infiltrating duct carcinoma, NOS type. 
 In conclusion, our study indicates that Her2/neu may be a more powerful 
predictor for poor prognosis as its expression is associated with important prognostic 
parameters like increased tumour size,  high tumour grade, high NPI score and 
lymph node involvement. 
 In future it is necessary to carry out studies with large samples of carcinoma 
breast and using other molecular prognostic markers to evaluate the prognosis and to 
provide better therapeutic options. 
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Summary 
  
SUMMARY 
 
 In the present study, 50 mastectomy specimens of carcinoma breast with 
axillary clearance were studied from November 2014 to august 2015. The 
gross and microscopic features with special emphasis on various 
clinicopathological prognostic parameters were studied. 
 
 All these cases were subjected to IHC for Her2/neu, the results of which 
were correlated with various clinicopathological prognostic parameters of 
carcinoma breast. 
 
 Majority of the cases were in the age group 40-59 years (70%). 
 
 Majority of cases had a tumour size of 2 to 5 cms (64%). 
 
 Majority of the cases (98%) were of infiltrating ductal carcinoma NOS 
type and 2% of invasive papillary carcinoma. 
 
 Majority of cases (90%) were of NSBR grade 2. 
 
 Majority of the cases (52%) showed axillary lymph node metastases. 
 
 Majority of the cases were in the MPG II (32%) group, followed by MPG I 
(28%), PPG (18%), GPG (16%), EPG (4%) and VPG (2%) groups. 
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 A statistically significant association of Her2/neu with lymph node status 
was noted in the present study (p value = 0.012). 
 
 No statistically significant association of Her2/neu with menopausal status 
was noted in the present study (p value = 0.449). 
 
 No statistically significant association of Her2/neu with tumour size was  
noted in the present study (p value = 0.374). However the percentage of the 
Her2/neu expression was more in tumour size of > 2 cms. 
 
 Her2/neu expression was seen only in infiltrating duct carcinoma, NOS type 
and no statistically significant association of Her2/neu with the histologic 
subtype was noted in the present study. 
 
 No statistically significant association of Her2/neu with histologic grade 
was noted in the present study (p value = 0.340). However the 
percentage of the Her2/neu expression was more in higher grade tumours. 
 
 Statistically significant association of Her2/neu with lymph node staging was 
noted in the present study (p value = 0.012). However the percentage of 
the Her2/neu expression was more in cases with lymph node involvement. 
 
 No statistically significant association of Her2/neu with NPI group was noted 
in the present study (p value = 0.235). 
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Annexure 
                                                                        PROFORMA 
 
Name : 
Age/Sex: 
IP no: 
Address: 
 
Contact no: 
Date of  Admission: 
Date of   Discharge: 
Presenting complaints: 
 h/o. mass 
 h/o. pain 
 h/o. discharge from the nipple 
Past history: 
 h/o. Diabetes/Hypertension/Liver/Kidney/Thyroid diseases 
 h/o. Radiation exposure 
 h/o.Previous surgeries 
Diet history: Vegetarian/Non vegetarian 
Family history: 
Menstrual history: 
 Age at menarche 
 Irregular mensus – any treatment taken specify 
 Hormone replacement: yes/no 
Estrogen only/estrogen + progesterone 
   OCP intake: yes/no 
 Age at birth of 1st child 
 Breast feeding 
 No. Of children 
 Age at  menopause 
General Examination: 
 Anaemia 
 Obesity 
 Blood Pressure 
 Pulse rate 
 Cardiovascular system 
 Respiratory system 
 Examination of abdomen 
Examination of  breast:  
Investigations: 
           Basic blood investigations 
           USG abdomen 
           USG breast 
           FNAC 
           Trucut biopsy 
           Metastatic workup 
Clinical staging (AJCC): 
 
 
 
 Pathological factors: 
   Gross  features: 
            Location 
          Multicentricity 
          Bilaterality 
          Tumor size 
          Tumor margins 
          Surgical margins 
          Underlying muscle involvement 
          Skin involvement 
          Nipple involvement 
          Lymph node 
  Microscopy 
          Insitu/Invasive 
          Lymphovascular invasion 
          Lymph node 
          Surgical margins 
          Underlying muscle involvement 
          Skin involvement 
          Nipple involvement 
          Histological subtype 
          Necrosis 
          Fibrosis 
          Stromal reaction 
          Pagetoid spread 
           
 Histological grading: 
           Tubules 
            Nuclear pleomorphism 
            Mitosis 
            Total score 
NSBR grade: I/II/III 
HER2/neu 
NPI 
Type of  therapy: 
            Surgery 
            Chemotherapy 
            Radiotherapy 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A STUDY OF  EXPRESSION OF  HER2/neu  IN    CARCINOMA     BREAST   WITH  
REFERENCE  TO CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC INDEX 
  
 
 
KEY TO MASTER CHART 
 
 
Sl No              serial number 
 
IP no              In patient number 
 
Nip Dis              Nipple discharge 
 
Menopaus              Menopause 
 
Clin Stage              Clinical stage 
 
Tum size              Tumour size 
 
Tubule              Tubule formation 
 
Nuc pleo              Nuclear pleomorphism 
 
LN              Lymph node 
 
NPI              Nottingham Prognostic Index. 
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1 FARDUNISHA 37407 48 1 0 0 0 5 IDC 3 2 2 2 23 0 4 MPG I 0 
2 AYESHA 25716 42 1 1 0 0 3.5 IDC 2 2 2 2 27 21 5.7 PPG 0 
3 ANSARI 13596 55 1 0 0 1 5 IDC 2 2 2 2 14 2 5 MPG II 3+ 
4 GAJENDRI 28235 55 1 0 0 1 5.3 IDC 3 2 2 2 14 7 6.06 PPG 0 
5 INDRA 14685 53 1 1 1 1 1.5 IDC 2 2 2 2 5 1 3.3 GPG 3+ 
6 MALLIGA 34847 55 1 0 0 1 7 IDC 2 3 2 2 4 3 5.4 MPG II 0 
7 MANJULA 23011 52 1 0 0 1 2.5 IDC 2 2 2 2 18 0 3.5 MPG I 0 
8 POWNU 24098 50 1 0 0 1 4 IDC 2 2 2 2 21 0 3.8 MPG I 1+ 
9 DEVI 14663 38 1 1 0 0 2.5 IDC 3 2 2 2 11 0 3.5 MPG I 0 
10 AMEENA 14022 45 1 1 0 0 2 IDC 2 2 2 2 10 0 3.4 GPG 0 
11 CHANDRA 4845 48 1 0 0 1 6 IDC 3 3 2 3 4 0 5.2 MPG II 0 
12 VELAMMAL 28236 72 1 0 0 1 2 IDC 2 2 2 2 29 0 3.4 GPG 0 
13 PARVATHY 13597 54 1 0 0 1 4 IDC 2 2 2 2 21 5 5.8 PPG 0 
14 THARABHAI 23207 60 1 0 0 1 3 IDC 2 2 2 2 17 2 4.6 MPG II 1+ 
15 MUNIRUNISHA 44376 45 1 0 0 0 2 IDC 2 2 2 2 12 0 3.4 GPG 0 
16 SAVITHRI 18484 40 1 0 0 0 4 IDC 2 2 2 2 17 2 4.8 MPG II 3+ 
17 RANI 30171 41 1 1 0 0 1.5 IDC 2 2 2 2 22 0 3.3 GPG 0 
18 SHAKUNTHALA 14686 45 1 0 0 0 4.8 IDC 2 2 2 2 10 5 5.96 PPG 3+ 
19 VIJAYA 9193 58 1 0 0 1 4.5 IDC 2 2 2 2 21 8 5.9 PPG 0 
20 VIRUTHAMBAL 14023 53 1 0 0 1 5 IDC 2 3 2 2 12 3 5 MPG II 3+ 
21 ANJALAI 36991 47 1 0 0 1 4 IDC 2 2 2 2 38 4 4.8 MPG II 2+ 
22 NAGAPUSHPAM 41005 48 1 0 1 1 5 IPC 3 2 2 2 15 0 4 MPG I 0 
23 MALLIKA 40389 48 1 0 0 1 8 IDC 2 3 2 2 24 8 6.6 VPG 3+ 
24 ANUSIYA 40487 60 1 0 0 1 4 IDC 2 2 2 2 11 10 5.8 PPG 0 
25 REVATHY 45572 50 1 0 0 1 5 IDC 3 2 2 2 23 0 4 MPG I 0 
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26 PADMINI 29808 46 1 0 0 1 3.5 IDC 2 2 2 2 27 21 5.7 PPG 0 
27 RUKMANI 28231 45 1 0 1 0 5 IDC 2 2 2 2 14 3 5 MPG II 3+ 
28 MAHALAKSHMI 23011 56 1 0 0 1 5.3 IDC 3 2 2 2 14 7 5.06 MPG II 0 
29 PREMA 23176 47 1 0 0 1 7 IDC 2 3 2 2 18 0 4.4 MPG I 0 
30 BAKKIYAM 21599 51 1 0 0 1 2.5 IDC 3 2 2 2 11 0 3.5 MPG I 0 
31 VALLIKANNU 20062 30 1 0 0 1 2.7 IDC 2 2 2 2 21 0 3.54 MPG I 0 
32 RUBI 13121 38 1 0 0 0 2 IDC 2 2 2 1 10 0 2.4 EPG 0 
33 SATHIYA 9871 50 1 0 0 1 6.2 IDC 3 3 2 3 4 0 5.24 MPG II 0 
34 PARAMESWARI 5721 51 1 1 1 1 1.7 IDC 2 2 2 2 5 2 3.34 GPG 3+ 
35 RABIYA BEE  5780 72 1 0 0 1 4.7 IDC 2 2 2 2 10 0 3.94 MPG I 3+ 
36 SHANTHI  37408 55 1 1 0 1 4 IDC 2 2 2 2 11 10 5.8 PPG 3+ 
37 DHANALAKSHMI 36992 47 1 0 0 1 2 IDC 2 2 2 2 17 2 4.4 MPG II 0 
38 ANJALA 41006 55 1 0 0 1 4 IDC 2 2 2 2 21 5 5.8 PPG 0 
39 KARPAGAVALLI 40388 59 1 0 0 1 3 IDC 2 2 2 2 17 2 4.6 MPG II 0 
40 THALABAI 40486 63 1 0 0 1 2 IDC 2 2 2 2 12 0 3.4 GPG 0 
41 LAKSHMI 45573 56 1 0 0 1 4 IDC 2 2 2 2 17 2 4.8 MPG II 0 
42 UMA 29809 48 1 0 0 1 1.5 IDC 2 2 2 1 5 0 2.3 EPG 0 
43 USHA DEVI  282232 33 1 1 1 0 5 IDC 2 2 2 2 11 2 5 MPG II 3+ 
44 TAMIL SELVI 23012 37 1 1 0 0 3 IDC 2 2 2 2 5 2 4.6 MPG II 3+ 
45 ABITHA BEE 23177 48 1 0 0 1 4 IDC 2 2 2 2 4 0 3.8 MPG I 0 
46 MANABOOBJAN 21598 37 1 0 0 0 4.2 IDC 2 2 2 2 14 3 4.84 MPG II 1+ 
47 KAMALA 20063 66 1 0 0 1 3.2 IDC 2 2 2 2 23 0 3.64 MPG I 0 
48 PUSHPA 13122 65 1 0 0 1 3 IDC 2 2 2 2 11 0 3.6 MPG I 1+ 
49 ALLI  9872 42 1 0 0 0 3 IDC 2 2 2 1 7 0 2.6 GPG 0 
50 MEGALA 5722 48 1 0 0 1 3.8 IDC 2 2 2 2 10 0 3.76 MPG I 2+ 
 
